胺碘酮联合厄贝沙坦治疗阵发性房颤疗效观察  

Therapeutic effect of irbesartan combined with aminodarone in patients with paroxysmal atrial fibrillation

作　　者：王用[1] 邢玉龙[1] 

机构地区：[1]江苏省高淳县人民医院心内科,江苏高淳211300

出　　处：《安徽医药》2013年第3期492-493,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察胺碘酮联合厄贝沙坦对阵发性房颤的疗效。方法将该科52例诊断为阵发性房颤的患者随机分为治疗组(26例)和对照组(26例)。对照组给予胺碘酮治疗,治疗组在胺碘酮的基础上加用厄贝沙坦联合治疗,观察两组患者1年内房颤复发、转为持续性房颤的发生情况。结果治疗组能够很好的维持窦性心律,1年内房颤复发及转为持续性房颤率明显低于对照组,差异具有统计学意义(P<0.05)。结论胺碘酮联合厄贝沙坦对阵发性房颤具有显著效果,不良反应少,值得临床推广。Objective To study the therapeutic effect of irbesartan combined with amiodarone in patients with paroxysmal atrial fibrillation（PAF）.Methods A total of 52 PAF patients diagnosed by our department were divided into therapeutic group（n=26） and control group（n=26）.Both groups received amiodarone,and the therapeutic group received irbesartan additionally.All patients were followed up for 1 year.Changes of recurrence rate of atrial fibrillation and aggravated into persistent atrial fibrillation before and after treatment were observed and compared between the two groups.Results Compared with the control group,there was significant decrease in recurrence rate of atrial fibrillation and aggravated into persistent atrial fibrillation in therapeutic group,P0.05.Conclusion With few adverse effect,irbesartan combined with amiodarone was effective in patients with PAF,which deserved generalization.

关 键 词：胺碘酮 厄贝沙坦 阵发性房颤 

分 类 号：R541.7[医药卫生—心血管疾病]